{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:52:20Z","timestamp":1747183940394},"reference-count":89,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,5,1]],"date-time":"2015-05-01T00:00:00Z","timestamp":1430438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["ackdjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2015,5]]},"DOI":"10.1053\/j.ackd.2014.10.002","type":"journal-article","created":{"date-parts":[[2015,4,21]],"date-time":"2015-04-21T01:16:24Z","timestamp":1429578984000},"page":"245-252","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Our Own Worst Enemy: Pharmacologic Mechanisms of Hypertension"],"prefix":"10.1053","volume":"22","author":[{"given":"Lynn E.","family":"Kassel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren E.","family":"Odum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1053\/j.ackd.2014.10.002_bib1","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ahj.2013.01.002","article-title":"Assessment of drug-induced increases in blood pressure during drug development: report from the Cardiac Safety Research Consortium","volume":"165","author":"Sager","year":"2013","journal-title":"Am Heart J"},{"issue":"1","key":"10.1053\/j.ackd.2014.10.002_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1177\/1074248414531852","article-title":"Food and Drug Administration regulation of drugs that raise blood pressure","volume":"20","author":"Blankfield","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"issue":"6","key":"10.1053\/j.ackd.2014.10.002_bib3","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1161\/HYPERTENSIONAHA.108.189141","article-title":"Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research","volume":"51","author":"Calhoun","year":"2008","journal-title":"Hypertension"},{"issue":"9349","key":"10.1053\/j.ackd.2014.10.002_bib4","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/S0140-6736(02)11911-8","article-title":"Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies","volume":"360","author":"Lewington","year":"2002","journal-title":"Lancet"},{"issue":"12","key":"10.1053\/j.ackd.2014.10.002_bib5","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1097\/HJH.0b013e32834c465d","article-title":"Drug-related hypertension and resistance to antihypertensive treatment: a call for action","volume":"29","author":"Rossi","year":"2011","journal-title":"J Hypertens"},{"issue":"4","key":"10.1053\/j.ackd.2014.10.002_bib6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.7326\/0003-4819-121-4-199408150-00011","article-title":"Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis","volume":"121","author":"Johnson","year":"1994","journal-title":"Ann Intern Med"},{"issue":"7343","key":"10.1053\/j.ackd.2014.10.002_bib7","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0140-6736(64)91804-5","article-title":"Side-effects of long-term\u00a0treatment with corticosteroids and corticotrophin","volume":"1","author":"Treadwell","year":"1964","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.ackd.2014.10.002_bib8","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.amjmed.2011.05.024","article-title":"Drug-induced hypertension: an unappreciated cause of secondary hypertension","volume":"124","author":"Grossman","year":"2012","journal-title":"Am J Med"},{"issue":"4","key":"10.1053\/j.ackd.2014.10.002_bib9","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00004872-198708000-00007","article-title":"Effects of ACTH and cortisol administration on blood pressure, electrolyte metabolism, atrial natriuretic peptide and renal function in normal man","volume":"5","author":"Connell","year":"1987","journal-title":"J Hypertens"},{"issue":"5","key":"10.1053\/j.ackd.2014.10.002_bib10","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1210\/jcem-72-5-1060","article-title":"Evidence that high dose cortisol-induced Na+ retention in man is not mediated by the mineralocorticoid receptor","volume":"72","author":"Montrella-Wabill","year":"1991","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1053\/j.ackd.2014.10.002_bib11","first-page":"S37","article-title":"Dose-response relationships and mineralocorticoid activity in cortisol-induced hypertension in humans","volume":"14","author":"Williamson","year":"1996","journal-title":"J Hypertens Suppl"},{"issue":"2","key":"10.1053\/j.ackd.2014.10.002_bib12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ecl.2011.01.010","article-title":"How do glucocorticoids cause hypertension: role of nitric oxide deficiency, oxidative stress, and eicosanoids","volume":"40","author":"Ong","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"7","key":"10.1053\/j.ackd.2014.10.002_bib13","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00467-011-1928-4","article-title":"Glucocorticoid-induced hypertension","volume":"27","author":"Goodwin","year":"2012","journal-title":"Pediatr Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2014.10.002_bib14","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(87)91014-2","article-title":"Mineralocorticoid actions of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age","volume":"23","author":"Stewart","year":"1987","journal-title":"Lancet"},{"issue":"4","key":"10.1053\/j.ackd.2014.10.002_bib15","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1521-690X(03)00053-8","article-title":"Cortisol and the renal handling of electrolytes: role in glucocorticoid-induced hypertension and bone disease","volume":"17","author":"Ferrari","year":"2003","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"11","key":"10.1053\/j.ackd.2014.10.002_bib16","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1093\/ndt\/4.11.979","article-title":"Correction of anemia of chronic renal failure\u00a0with recombinant erythropoietin: safety and efficacy at one year's treatment in a European multicenter study of 150 hemodialysis-dependent patients","volume":"4","author":"Sundoul","year":"1989","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.ackd.2014.10.002_bib17","first-page":"392","article-title":"Erythropoietin induces Ca2+ mobilization and contraction in rat mesangial and aortic smooth muscle cultures","volume":"24","author":"Morakkabati","year":"1996","journal-title":"Exp Hematol"},{"issue":"5","key":"10.1053\/j.ackd.2014.10.002_bib18","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0272-6386(99)70413-0","article-title":"Mechanism of erythropoietin-induced hypertension","volume":"33","author":"Vaziri","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2014.10.002_bib19","series-title":"Procrit [package insert]","year":"2013"},{"key":"10.1053\/j.ackd.2014.10.002_bib20","series-title":"Aranesp [package insert]","year":"2013"},{"key":"10.1053\/j.ackd.2014.10.002_bib21","unstructured":"Lexi-Drugs Online. Hudson, OH: Lexi-Comp, Inc. Accessed June\u00a02014."},{"issue":"1","key":"10.1053\/j.ackd.2014.10.002_bib22","first-page":"CD007893","article-title":"Effect of cyclosporine on blood pressure","author":"Robert","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1053\/j.ackd.2014.10.002_bib23","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5301\/jn.5000174","article-title":"Pathogenesis of calcineurin inhibitor\u2013induced hypertension","volume":"25","author":"Hoorn","year":"2012","journal-title":"J Nephrol"},{"issue":"2","key":"10.1053\/j.ackd.2014.10.002_bib24","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0002-9343(88)80331-0","article-title":"Hypertension in cyclosporine-treated renal transplant recipients is sodium dependent","volume":"85","author":"Curtis","year":"1988","journal-title":"Am J Med"},{"issue":"1","key":"10.1053\/j.ackd.2014.10.002_bib25","first-page":"76","article-title":"Endothelin mediates the renal vasoconstriction induced by cyclosporine in the rat","volume":"1","author":"Perico","year":"1990","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"10.1053\/j.ackd.2014.10.002_bib26","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1097\/01.ASN.0000071515.27754.67","article-title":"Improved cardiovascular risk profile and renal function in renal transplant patients after randomized conversion from cyclosporine to tacrolimus","volume":"14","author":"Artz","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ackd.2014.10.002_bib27","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1111\/j.1600-6143.2004.00427.x","article-title":"Conversion from cyclosporine to tacrolimus improves quality-of-life indices, renal graft function and cardiovascular risk profile","volume":"4","author":"Artz","year":"2004","journal-title":"Am J Transplant"},{"issue":"12","key":"10.1053\/j.ackd.2014.10.002_bib28","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1097\/00004872-200112000-00025","article-title":"Cyclosporin-induced hypertension","volume":"19","author":"Cifkova","year":"2001","journal-title":"J Hypertens"},{"issue":"4","key":"10.1053\/j.ackd.2014.10.002_bib29","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1176\/ajp.148.4.512","article-title":"Cardiovascular effects of bupropion in depressed patients with heart disease","volume":"148","author":"Roose","year":"1991","journal-title":"Am J Psychiatry"},{"key":"10.1053\/j.ackd.2014.10.002_bib30","series-title":"Zyban [package insert]","year":"2008"},{"key":"10.1053\/j.ackd.2014.10.002_bib31","series-title":"Wellbutrin XL [package insert]","year":"2008"},{"issue":"2","key":"10.1053\/j.ackd.2014.10.002_bib32","first-page":"72","article-title":"Hypertension induced by drugs and other substances","volume":"15","author":"Clyburn","year":"1995","journal-title":"Semin Nephrol"},{"issue":"4","key":"10.1053\/j.ackd.2014.10.002_bib33","first-page":"163","article-title":"\u2018Spontaneous\u2019 hypertensive episodes with monoamine oxidase inhibitors","volume":"49","author":"Fallon","year":"1998","journal-title":"J Clin Psychiatry"},{"issue":"6698","key":"10.1053\/j.ackd.2014.10.002_bib34","first-page":"964","article-title":"Hypertensive crisis and broad complex bradycardia after a single dose of monoamine oxidase inhibitor","volume":"298","author":"Gunn","year":"1987","journal-title":"BMJ"},{"issue":"10","key":"10.1053\/j.ackd.2014.10.002_bib35","doi-asserted-by":"crossref","first-page":"502","DOI":"10.4088\/JCP.v59n1002","article-title":"Effects of venlafaxine on blood pressure: a meta-analysis of original data from 3744 depressed patients","volume":"59","author":"Thase","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"10.1053\/j.ackd.2014.10.002_bib36","series-title":"Pristiq [package insert]","year":"2009"},{"issue":"suppl 14","key":"10.1053\/j.ackd.2014.10.002_bib37","first-page":"4","article-title":"Mechanism of action of antidepressant medications","volume":"60","author":"Feighner","year":"1999","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"10.1053\/j.ackd.2014.10.002_bib38","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/j.1751-7176.2008.07758.x","article-title":"Secondary hypertension: interfering substances","volume":"10","author":"Grossman","year":"2008","journal-title":"J Clin Hypertens"},{"issue":"5","key":"10.1053\/j.ackd.2014.10.002_bib39","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S0272-6386(00)70246-0","article-title":"Cocaine and the kidney: a synthesis of pathophysiologic and clinical and perspectives","volume":"35","author":"Nzerue","year":"2000","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ackd.2014.10.002_bib40","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s00467-005-2051-1","article-title":"Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial","volume":"21","author":"Samuels","year":"2006","journal-title":"Pediatr Nephrol"},{"key":"10.1053\/j.ackd.2014.10.002_bib41","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1001\/archotol.1963.00750010151006","article-title":"Hypertension and unconsciousness following: report of a case, ingestion of pseudoephedrine","volume":"77","author":"Rutstein","year":"1963","journal-title":"Arch Otolaryngol"},{"issue":"3","key":"10.1053\/j.ackd.2014.10.002_bib42","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1365-2125.1989.tb05441.x","article-title":"A controlled clinical trial on the cardiovascular effects of single doses of pseudoephedrine in hypertensive patients","volume":"28","author":"Chua","year":"1989","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1053\/j.ackd.2014.10.002_bib43","first-page":"201","article-title":"The effect of pseudoephedrine on blood pressure in patients with controlled, uncomplicated hypertension: a randomized, double-blind, placebo-controlled trial","volume":"4","author":"Bradley","year":"1991","journal-title":"J Am Board Fam Pract"},{"issue":"1","key":"10.1053\/j.ackd.2014.10.002_bib44","first-page":"22","article-title":"Does pseudoephedrine increase blood pressure in patients with controlled hypertension?","volume":"40","author":"Coates","year":"1995","journal-title":"J Fam Pract"},{"issue":"15","key":"10.1053\/j.ackd.2014.10.002_bib45","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1001\/archinte.165.15.1686","article-title":"Effect of oral pseudoephedrine on blood pressure and heart rate: a meta-analysis","volume":"165","author":"Salerno","year":"2005","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1053\/j.ackd.2014.10.002_bib46","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1136\/bjo.73.6.468","article-title":"Adverse effect of intraoperative phenylephrine 10%: case report","volume":"73","author":"Lai","year":"1989","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1053\/j.ackd.2014.10.002_bib47","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/S0002-9394(02)01591-X","article-title":"Adverse systemic effects from pledgets of topical ocular phenylephrine 10%","volume":"134","author":"Fraunfelder","year":"2002","journal-title":"Am J Ophthalmol"},{"issue":"25","key":"10.1053\/j.ackd.2014.10.002_bib48","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1056\/NEJM200012213432502","article-title":"Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids","volume":"343","author":"Haller","year":"2000","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.ackd.2014.10.002_bib49","doi-asserted-by":"crossref","first-page":"12","DOI":"10.4065\/77.1.12","article-title":"Cardiovascular events temporally associated with ma huang, an herbal source of ephedrine","volume":"77","author":"Samenuk","year":"2002","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1053\/j.ackd.2014.10.002_bib50","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/PRS.0b013e318272f1bb","article-title":"herbal products that may\u00a0contribute to hypertension","volume":"131","author":"Jalili","year":"2013","journal-title":"Plast Reconstr Surg"},{"key":"10.1053\/j.ackd.2014.10.002_bib51","unstructured":"FDA. FDA acts to remove ephedra-containing dietary supplements from\u00a0market. P04\u2013P106; 2004. Available at: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2004\/ucm108379.htm. Accessed July 15, 2014."},{"key":"10.1053\/j.ackd.2014.10.002_bib52","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/764584","article-title":"Experience (mostly negative) with the use of sympathomimetic agents for weight loss","author":"Inchiosa","year":"2011","journal-title":"J Obes"},{"key":"10.1053\/j.ackd.2014.10.002_bib53","unstructured":"Therapeutic Research Faculty. Yohimbe. Medline Plus, a service of the US National Library of Medicine, National Institutes of Health. Available at: http:\/\/www.nlm.nih.gov\/medlineplus\/druginfo\/natural\/759.html. Accessed July 11, 2014."},{"issue":"7","key":"10.1053\/j.ackd.2014.10.002_bib54","first-page":"585","article-title":"Cardiovascular risk and the use of oral contraceptives","volume":"34","author":"Kaminski","year":"2013","journal-title":"Neuroendocrinol Lett"},{"issue":"3","key":"10.1053\/j.ackd.2014.10.002_bib55","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.contraception.2012.12.002","article-title":"Combined oral contraceptive containing drosperinone does not modify 24-hr ambulatory blood pressure but increases heart rate in healthy young women: prospective study","volume":"88","author":"Cagnacci","year":"2013","journal-title":"Contraception"},{"issue":"12","key":"10.1053\/j.ackd.2014.10.002_bib56","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1001\/jama.1967.03130120026007","article-title":"Oral contraceptives, renin, aldosterone, and high blood pressure","volume":"201","author":"Laragh","year":"1967","journal-title":"JAMA"},{"issue":"1","key":"10.1053\/j.ackd.2014.10.002_bib57","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0002-8703(84)90144-3","article-title":"Plasma renin substrate, renin activity, and aldosterone levels in a sample of oral contraceptive users from a community survey","volume":"107","author":"Goldhaber","year":"1984","journal-title":"Am Heart J"},{"issue":"2","key":"10.1053\/j.ackd.2014.10.002_bib58","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ecl.2011.01.008","article-title":"Blood pressure effects of the oral contraceptive and postmenopausal hormone therapies","volume":"40","author":"Boldo","year":"2011","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"5","key":"10.1053\/j.ackd.2014.10.002_bib59","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ando.2012.09.001","article-title":"Hormonal contraception in women at risk of vascular and metabolic disorders: guidelines of the French Society of Endocrinology","volume":"73","author":"Gourdy","year":"2012","journal-title":"Ann Endocrinol"},{"issue":"4","key":"10.1053\/j.ackd.2014.10.002_bib60","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1590\/S0066-782X2011005000022","article-title":"Hormonal contraception and cardiovascular system","volume":"96","author":"Brito","year":"2011","journal-title":"Arq Bras Cardiol"},{"issue":"3","key":"10.1053\/j.ackd.2014.10.002_bib61","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jacc.2008.09.042","article-title":"Contraceptive hormone use and cardiovascular disease","volume":"53","author":"Shufelt","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1053\/j.ackd.2014.10.002_bib62","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1097\/00006250-200606000-00055","article-title":"Use of hormonal contraception in women with coexisting medical conditions. ACOG Practice Bulletin No. 73. American College of Obstetrics and Gynecologists","volume":"107","year":"2006","journal-title":"Obstet Gynecol"},{"issue":"5","key":"10.1053\/j.ackd.2014.10.002_bib63","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.contraception.2012.09.017","article-title":"Appropriate follow up to detect potential adverse events after initiation of select contraceptive methods: a systematic review","volume":"87","author":"Steenland","year":"2013","journal-title":"Contraception"},{"issue":"39","key":"10.1053\/j.ackd.2014.10.002_bib64","first-page":"1","article-title":"Associations between oral contraceptive use and risks of hypertension and prehypertension in a cross-sectional study of Korean women","volume":"13","author":"Park","year":"2013","journal-title":"BMC Womens Health"},{"issue":"suppl 2","key":"10.1053\/j.ackd.2014.10.002_bib65","first-page":"S62","article-title":"Effect of postmenopausal hormone therapy on cardiovascular risk","volume":"20","author":"Rossouw","year":"2002","journal-title":"J Hypertens"},{"key":"10.1053\/j.ackd.2014.10.002_bib66","series-title":"Androderm [package insert]","year":"2013"},{"key":"10.1053\/j.ackd.2014.10.002_bib67","series-title":"Androgel [package insert]","year":"2013"},{"issue":"10","key":"10.1053\/j.ackd.2014.10.002_bib68","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1345\/aph.1A020","article-title":"Hypertension as a complication of topical\u00a0testosterone therapy","volume":"35","author":"Tangredi","year":"2001","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1053\/j.ackd.2014.10.002_bib69","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1097\/HJH.0b013e3283603eb1","article-title":"Positive association between testosterone, blood pressure, and hypertension in women: longitudinal findings from the Study of Health in Pomerania","volume":"31","author":"Ziemens","year":"2013","journal-title":"J Hypertens"},{"issue":"7","key":"10.1053\/j.ackd.2014.10.002_bib70","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1097\/SMJ.0b013e318063c3e8","article-title":"Secondary hypertension due to drugs and toxins","volume":"100","author":"Gyamlani","year":"2007","journal-title":"South Med J"},{"issue":"2","key":"10.1053\/j.ackd.2014.10.002_bib71","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s10456-012-9327-4","article-title":"Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension","volume":"16","author":"Kruzliak","year":"2013","journal-title":"Angiogenesis"},{"issue":"1","key":"10.1053\/j.ackd.2014.10.002_bib72","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ajh\/hpt201","article-title":"Vascular endothelial growth factor\u00a0inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors","volume":"27","author":"Kruzliak","year":"2014","journal-title":"Am J Hypertens"},{"issue":"4","key":"10.1053\/j.ackd.2014.10.002_bib73","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1188\/05.CJON.407-411","article-title":"Hypertension associated with bevacizumab","volume":"9","author":"Rosiak","year":"2005","journal-title":"Clin J Oncol Nurs"},{"issue":"28","key":"10.1053\/j.ackd.2014.10.002_bib74","doi-asserted-by":"crossref","first-page":"11306","DOI":"10.1073\/pnas.1203275109","article-title":"Endostatin lowers blood pressure via nitric oxide and prevents hypertension associated with VEGF inhibition","volume":"109","author":"Sunshine","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"19","key":"10.1053\/j.ackd.2014.10.002_bib75","doi-asserted-by":"crossref","first-page":"6250","DOI":"10.1158\/1078-0432.CCR-09-0058","article-title":"Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment","volume":"15","author":"Maitland","year":"2009","journal-title":"Clin Cancer Res"},{"issue":"36","key":"10.1053\/j.ackd.2014.10.002_bib76","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1200\/JCO.2009.22.2273","article-title":"Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase ii randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors","volume":"27","author":"Langenberg","year":"2009","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1053\/j.ackd.2014.10.002_bib77","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.1158\/1078-0432.CCR-09-1717","article-title":"Rapid development of hypertension by sorafenib: toxicity or target?","volume":"15","author":"Humphreys","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.ackd.2014.10.002_bib78","doi-asserted-by":"crossref","first-page":"816897","DOI":"10.4061\/2011\/816897","article-title":"Vascular endothelial growth factor inhibitor-induced hypertension: basics for primary care providers","volume":"2011","author":"Escalante","year":"2011","journal-title":"Cardiol Res Pract"},{"issue":"3","key":"10.1053\/j.ackd.2014.10.002_bib79","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2215\/CJN.08111109","article-title":"Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor","volume":"5","author":"Robinson","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.10.002_bib80","series-title":"Drug Induced Diseases: Prevention, Detection, and Management","first-page":"516","article-title":"Hypertension","author":"Saseen","year":"2010"},{"issue":"4","key":"10.1053\/j.ackd.2014.10.002_bib81","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1161\/HYPERTENSIONAHA.109.149690","article-title":"Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels","volume":"56","author":"Kappers","year":"2010","journal-title":"Hypertension"},{"issue":"3","key":"10.1053\/j.ackd.2014.10.002_bib82","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.clcc.2011.03.021","article-title":"An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition","volume":"10","author":"Copur","year":"2011","journal-title":"Clin Colorectal Cancer"},{"issue":"5","key":"10.1053\/j.ackd.2014.10.002_bib83","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/j.1440-1681.2012.05699.x","article-title":"Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib","volume":"39","author":"Nagasawa","year":"2012","journal-title":"Clin Exp Pharmacol Physiol"},{"issue":"2","key":"10.1053\/j.ackd.2014.10.002_bib84","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis"},{"issue":"14","key":"10.1053\/j.ackd.2014.10.002_bib85","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1161\/CIRCULATIONAHA.107.188950","article-title":"Management of cocaine-associated chest pain and myocardial infarction: a scientific statement from the American Heart Association Acute Cardiac Care Committee of the Council of Clinical Cardiology","volume":"117","author":"McCord","year":"2008","journal-title":"Circulation"},{"issue":"2","key":"10.1053\/j.ackd.2014.10.002_bib86","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1291\/hypres.27.79","article-title":"Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients","volume":"27","author":"Miyashita","year":"2004","journal-title":"Hypertens Res"},{"key":"10.1053\/j.ackd.2014.10.002_bib87","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ejogrb.2014.01.006","article-title":"Effects of a contraceptive containing drospirenone and ethinyl estradiol on blood pressure and autonomic tone: a prospective controlled clinical trial","volume":"175","author":"Nisenbaum","year":"2014","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1053\/j.ackd.2014.10.002_bib88","first-page":"745","article-title":"Modification of blood pressure in postmenopausal women: role of hormone replacement therapy","volume":"6","author":"Cannoletta","year":"2014","journal-title":"Int J Womens Health"},{"issue":"10","key":"10.1053\/j.ackd.2014.10.002_bib89","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/nm.2497","article-title":"The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension","volume":"17","author":"Hoorn","year":"2011","journal-title":"Nat Med"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559514001669?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559514001669?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T21:13:37Z","timestamp":1566594817000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559514001669"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,5]]},"references-count":89,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["S1548559514001669"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2014.10.002","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2015,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Our Own Worst Enemy: Pharmacologic Mechanisms of Hypertension","name":"articletitle","label":"Article Title"},{"value":"Advances in Chronic Kidney Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ackd.2014.10.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}